• Jeremy Slater, M.D.
    x

    Jeremy Slater, M.D.

    Chief Medical Officer, The Alliance Family of Companies
    University of Pittsburgh School of Medicine, M.D.

    Dr. Slater has worked in the field of epilepsy for more than 27 years. He served as the Director of the Texas Comprehensive Epilepsy Program from 2004 to 2018, growing the center from a single neurologist and neurosurgeon to one of the largest epilepsy surgery programs in the country. He has served as an investigator for numerous clinical trials of novel anticonvulsants and medical devices. His early research work focused on the potential for applying techniques of the developing field of artificial neural networks to classification problems in clinical neurophysiology. These studies demonstrated the ability of such networks to distinguish disease states with a level of discrimination higher than achieved through statistical or human visual analysis. While the architectures have evolved and now such analyses are commonplace, these were the first such studies of their kind. His more recent research has focused on changes to brain electrical activity related to drowsiness. In 2018, Dr. Slater joined the Alliance Family of Companies as Chief Medical Officer.

  • Thomas Cochrane, M.D.
    x

    Thomas Cochrane, M.D.

    Medical Director, Biogen
    Tufts University School of Medicine, M.D.

    Thomas Cochrane completed his residency in neurology in the Partners Neurology program at Massachusetts General Hospital and Brigham and Women’s Hospital. He then completed a fellowship in neuromuscular medicine and electromyography at Brigham and Women’s Hospital. He completed the Fellowship in Medical Ethics at Harvard Medical School, and then served as a Faculty Fellow at the Safra Foundation Center for Ethics at Harvard University. Since 2005, he has worked as an attending neurologist specializing in neuromuscular disease at Brigham and Women’s Hospital. He also worked as the Senior Ethics Consultant at BWH and served on the Partners IRB. He taught medical ethics to Harvard Medical students, residents, faculty, and nursing staff at all levels, and was the first Director of Neuroethics at the Center for Bioethics at Harvard Medical School. In 2018, he joined Biogen as a Medical Director, and is responsible for medical oversight of natalizumab (Tysabri), a drug for multiple sclerosis, in the U.S.

  • Richard Verrier, Ph.D.
    x

    Richard Verrier, Ph.D.

    Associate Professor, Environmental Health Harvard University
    Director of Cardiology Grand Rounds, Beth Israel Deaconess Medical Center
    University of Virginia, Ph.D.

    Dr. Verrier has investigated sudden cardiac death for more than 3 decades, having published more than 300 original articles. He is inventor of 12 licensed patents for diagnosis and treatment of heart rhythm abnormalities and prediction of sudden cardiac death. During the past 6 years, he has focused attention on cardiac effects of epilepsy with close collaborations with Professor Steven Schachter, a pioneer in VNS therapy and Past President of AES. Their joint publications in Epilepsia and Epilepsy & Behavior have broken new ground in the study of patients with epilepsy.

  • Robert Knowlton, M.D.
    x

    Robert Knowlton, M.D.

    Professor, Neurology, University of California San Francisco
    Medical Director, UCSF Seizure Disorders Surgery Program
    Louisiana State University School of Medicine New Orleans, M.D.

    Dr. Knowlton’s research focuses on discovering advances in clinical neurophysiology and brain imaging that can affect decision-making in treatment of seizure disorders and brain tumors. The main focus of his work is to determine which advanced imaging discoveries should be moved to clinical application. He has worked specifically to improve and validate the clinical utilization of multiple modalities of brain imaging, including high-resolution magnetic resonance imaging (MRI), MR spectroscopy/spectroscopic imaging (MRS/MRSI), positron emission tomography (PET), magnetic and electrical source imaging (MSI/ESI), and ictal single photon emission computed tomography (SPECT). From the very beginning of his career, he has taken advantage of combining multiple imaging modalities to allow comparison of the relative merits for each test, to determine if novel information can be discerned, and measure whether purported advances improve patient care.

  • Pavel Klein, M.D.
    x

    Pavel Klein, M.D.

    Director, Mid-Atlantic Epilepsy and Sleep Center
    Associate Professor, Neurology, George Washington University
    Cambridge University, M.D.

    Dr. Klein’s clinical research includes novel treatments of epilepsy, dietary treatments of epilepsy in adults, prevention of epilepsy after traumatic brain injury, the effect of sex and stress hormones on epilepsy, and women with epilepsy. He has received grants from the National Institutes of Health, from the American Epilepsy Society, and investigator-initiated study grants from several pharmaceutical companies. Dr. Klein has published more than 45 peer-reviewed articles and contributed chapters to several books on epilepsy. He acts as a reviewer for a number of neurological, epilepsy and endocrinological journals. He has been a member of the American Epilepsy Society Scientific Program Committee, Treatment Committee, the Health Reform Task Force, and is currently the Chair of the AES Corporate Advisory Council. He is the co-founder and co-chair of the North American Consortium of Private Epilepsy Practices.

  • R. Eugene Ramsay, M.D.
    x

    R. Eugene Ramsay, M.D.

    Comprehensive Epilepsy Center, Ochsner Medical Center
    University of Florida College of Medicine, M.D.

    Dr. Ramsay is a Fellow of the American Academy of Neurology, and member of the American Electroencephalographic Society, the American Epilepsy Society, and the American Neurological Association. Dr. Ramsay has trained 28 fellows during time and several are now leading epileptologists at other epilepsy centers. Dr. Ramsay is chief editor of the book Neurobiology of Epilepsy and Aging and with A. James Rowan, of the textbook Seizures and Epilepsy in the Elderly. He is author or coauthor of more than 120 articles published in peer-reviewed journals, 28 book chapters and a book. He is the recipient of more than 80 grants for research in the treatment of epilepsy. One of his leading accomplishments has been the completion of a large multicenter study on the treatment of epilepsy in a geriatric population.

  • David Arciniegas, M.D.
    x

    David Arciniegas, M.D.

    Chief Medical Officer, Center for Mental Health
    Clinical Professor, Neurology & Psychiatry, University of Colorado School of Medicine
    Clinical Professor, Psychiatry, Neurology, Physical Medicine & Rehabilitation, Baylor College of Medicine
    Senior Scientist, Brain Injury Research Center at TIRR Memorial Hermann
    University of Michigan Medical School, M.D.

    Over the last 20 years, Dr. Arciniegas clinical work and patient-oriented research as a subspecialist in Behavioral Neurology & Neuropsychiatry has focused on the phenomenology, neurobiology, and rehabilitation of the cognitive and non-cognitive neuropsychiatric sequelae of traumatic brain injury (TBI), other acquired brain injuries and neurodegenerative disorders, and neurodevelopmental conditions, including schizophrenia spectrum and other psychotic disorders. He has authored more than 115 peer-reviewed journal articles, over 130 peer-reviewed abstracts, nearly three dozen book chapters, and more than 40 additional media-related works for professional and lay audiences. He is Editor of the Journal of Neuropsychiatry and Clinical Neurosciences and a member of multiple editorial and scientific review boards in the clinical neurosciences. In addition to his administrative, clinical, and academic duties, Dr. Arciniegas serves as Chairman and CEO of the International Brain Injury Association, is President-Elect of the International Neuropsychiatric Association, and contributes his efforts to governmental and non-governmental organizations striving to improve the lives of persons and families affected by brain injuries.

  • Don Rojas, Ph.D.
    x

    Don Rojas, Ph.D.

    Professor, Department Chair of Psychology, Colorado State University
    Colorado State University, Ph.D.

    Since 2013, Don Rojas has served as a faculty member in the Department of Psychology at Colorado State University. The primary theme of his work has been the identification of heritable biomarkers in autism, using non-invasive neuroimaging and electrophysiological techniques in first-degree relatives. His specialties include magnetoencephalography, electroencephalography, functional magnetic resonance imaging, autism, and schizophrenia.